Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Emãnuella M. Garcez"'
Autor:
Maria Victória Souto-Silva, Elizabete C. I. Bispo, Lucas F. F. Albuquerque, Stefhani Barcelos, Emãnuella M. Garcez, Luana S. Quilici, Florêncio Figueiredo Cavalcanti Neto, Eliza Carla Barroso Duarte, Jankerle N. Boeloni, Felipe Saldanha-Araujo, Guilherme M. Gelfuso, Juliana Lott Carvalho
Publikováno v:
Pharmaceutics, Vol 16, Iss 11, p 1377 (2024)
Background/Objectives: Ibrutinib (IBR) is a tyrosine kinase inhibitor under investigation in preclinical and clinical settings as an alternative treatment for melanoma. Nevertheless, the limited oral bioavailability of IBR and the need for high doses
Externí odkaz:
https://doaj.org/article/a757fb23569542d8a8ffb47b08adc185
Autor:
Souto-Silva, Maria Victória1 (AUTHOR), Bispo, Elizabete C. I.2 (AUTHOR) felipearaujo@unb.br, Albuquerque, Lucas F. F.3 (AUTHOR) gmgelfuso@unb.br, Barcelos, Stefhani1 (AUTHOR), Garcez, Emãnuella M.1 (AUTHOR), Quilici, Luana S.1 (AUTHOR), Neto, Florêncio Figueiredo Cavalcanti4 (AUTHOR), Duarte, Eliza Carla Barroso5 (AUTHOR), Boeloni, Jankerle N.6 (AUTHOR), Saldanha-Araujo, Felipe2 (AUTHOR), Gelfuso, Guilherme M.3 (AUTHOR), Carvalho, Juliana Lott1,5 (AUTHOR) julianalott@gmail.com
Publikováno v:
Pharmaceutics. Nov2024, Vol. 16 Issue 11, p1377. 18p.